REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases ...

Positioned as the only approved therapy for PWS-related hyperphagia, VYKAT XR is expected to make a meaningful impact due to its broad patient coverage and robust support via the Soleno One program.